$1.180
+0.010 (+0.85%)Al cierre
- Máximo
- 1.220
- Apertura
- 1.172
- Precio medio ponderado por volumen
- 1.19
- Volumen
- 23.20K
- Capitalización
- —
- Mínimo
- 1.160
- Importe
- 27.53K
- EV/EBITDA, TTM
- 0.00
Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.
Análisis de IA of Regentis Biomaterials Ltd (RGNT)
VenderRegentis Biomaterials Ltd is not a good buy right now due to its extremely low RSI of 26.439, indicating oversold conditions, and a staggering year-to-date decline of 82.49%.
Métricas de valoración
Cronología de eventos
Noticias
8.509-11Yahoo FinanceRegentis Advances GelrinC® U.S. Pivotal Trial and European Commercialization
8.507-08Yahoo FinanceRegentis Biomaterials Files Registration Statement
2.007-02NASDAQ.COMBiotech Companies See Significant Stock Gains
8.506-18seekingalphaRegentis Biomaterials Raises $6.5 Million in Private Placement
- 2.006-16NASDAQ.COM
Regentis Soars After Withdrawing US Listing Application
Preguntas frecuentes sobre RGNT, respondidas por Alphio AI
Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis. It operates in the Healthcare sector.
Regentis Biomaterials Ltd is not a good buy right now due to its extremely low RSI of 26.439, indicating oversold conditions, and a staggering year-to-date decline of 82.49%.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.